Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 4
2000 1
2001 4
2002 2
2004 3
2005 2
2006 1
2007 2
2008 3
2009 1
2010 2
2011 3
2012 1
2014 1
2015 1
2016 1
2017 2
2018 1
2021 5
2023 3
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: charo j. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, Del Nagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N. Peters S, et al. Among authors: charo j. Clin Cancer Res. 2024 Apr 15;30(8):1630-1641. doi: 10.1158/1078-0432.CCR-23-2658. Clin Cancer Res. 2024. PMID: 38319672
Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R, Levin A, Odero C, Pecenka C, Tabu C, Mwendo E, Bonsu G, Bawa J, Dadzie JF, Charo J, Antwi-Agyei KO, Amponsa-Achianou K, Jalango RE, Mkisi R, Gordon S, Mzengeza T, Morgan W, Muhib F. Baral R, et al. Among authors: charo j. PLoS One. 2021 Jan 11;16(1):e0244995. doi: 10.1371/journal.pone.0244995. eCollection 2021. PLoS One. 2021. PMID: 33428635 Free PMC article.
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.
Textor A, Schmidt K, Kloetzel PM, Weißbrich B, Perez C, Charo J, Anders K, Sidney J, Sette A, Schumacher TN, Keller C, Busch DH, Seifert U, Blankenstein T. Textor A, et al. Among authors: charo j. J Exp Med. 2016 Oct 17;213(11):2333-2348. doi: 10.1084/jem.20160636. Epub 2016 Oct 3. J Exp Med. 2016. PMID: 27697836 Free PMC article.
Systemic Immune Response to a CD40-Agonist Antibody in Nonhuman Primates.
Caudell DL, Dugan GO, Babitzki G, Schubert C, Braendli-Baiocco A, Wasserman K, Acona G, Stern M, Passioukov A, Cline JM, Charo J. Caudell DL, et al. Among authors: charo j. J Leukoc Biol. 2024 Feb 19:qiae031. doi: 10.1093/jleuko/qiae031. Online ahead of print. J Leukoc Biol. 2024. PMID: 38372596
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Charo J, et al. Cancer Res. 2005 Mar 1;65(5):2001-8. doi: 10.1158/0008-5472.CAN-04-2006. Cancer Res. 2005. PMID: 15753400 Free PMC article.
50 results